The Therapeutic Potential of MicroRNAs in Atrial Fibrillation

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2020 Apr 8

PMID 32256190

Citations 10

Authors

Xiaona Xu

Zhiqiang Zhao

Guangping Li

Affiliations

Soon will be listed here.

Abstract

One of the most globally prevalent supraventricular arrhythmias is atrial fibrillation (AF). Knowledge of the structures and functions of messenger RNA (mRNA) has recently increased. It is no longer viewed as solely an intermediate molecule between DNA and proteins but has come to be seen as a dynamic and modifiable gene regulator. This new perspective on mRNA has led to rising interest in it and its presence in research into new therapeutic schemes. This paper, therefore, focuses on microRNAs (miRNAs), which are small noncoding RNAs that regulate posttranscriptional gene expression and play a vital role in the physiology and normative development of cardiovascular systems. This means they play an equally vital role in the development and progression of cardiovascular diseases. In recent years, multiple studies have pinpointed particular miRNA expression profiles as being associated with varying histological features of AF. These studies have been carried out in both animal models and AF patients. The emergence of miRNAs as biomarkers and their therapeutic potential in AF patients will be discussed in the body of this paper.

Citing Articles

Transcriptomics, Proteomics and Bioinformatics in Atrial Fibrillation: A Descriptive Review.

Belfiori M, Lazzari L, Hezzell M, Angelini G, Dong T Bioengineering (Basel). 2025; 12(2).

PMID: 40001669 PMC: 11851880. DOI: 10.3390/bioengineering12020149.

Deciphering the Role of microRNAs: Unveiling Clinical Biomarkers and Therapeutic Avenues in Atrial Fibrillation and Associated Stroke-A Systematic Review.

Boxhammer E, Dienhart C, Rezar R, Hoppe U, Lichtenauer M Int J Mol Sci. 2024; 25(10.

PMID: 38791605 PMC: 11122365. DOI: 10.3390/ijms25105568.

MicroRNAs in Atrial Fibrillation: Mechanisms, Vascular Implications, and Therapeutic Potential.

Vardas E, Theofilis P, Oikonomou E, Vardas P, Tousoulis D Biomedicines. 2024; 12(4).

PMID: 38672166 PMC: 11048414. DOI: 10.3390/biomedicines12040811.

Circulating MicroRNAs as Specific Biomarkers in Atrial Fibrillation: A Meta-Analysis.

Junior A, Ferreira L, Barbosa L, de Melo E Silva D, Saddi V, Silva A Noncoding RNA. 2023; 9(1).

PMID: 36827546 PMC: 9967089. DOI: 10.3390/ncrna9010013.

MicroRNA-205-5p plays a suppressive role in the high-fat diet-induced atrial fibrosis through regulation of the EHMT2/IGFBP3 axis.

Xiao Z, Xie Y, Huang F, Yang J, Liu X, Lin X Genes Nutr. 2022; 17(1):11.

PMID: 35858845 PMC: 9297569. DOI: 10.1186/s12263-022-00712-z.

References

Kriegel A, Liu Y, Fang Y, Ding X, Liang M . The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics. 2012; 44(4):237-44. PMC: 3289120. DOI: 10.1152/physiolgenomics.00141.2011. View

Burashnikov A, Antzelevitch C . Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity. Circulation. 2003; 107(18):2355-60. DOI: 10.1161/01.CIR.0000065578.00869.7C. View

Iwakawa H, Tomari Y . The Functions of MicroRNAs: mRNA Decay and Translational Repression. Trends Cell Biol. 2015; 25(11):651-665. DOI: 10.1016/j.tcb.2015.07.011. View

Weckbach L, Grabmaier U, Clauss S, Wakili R . MicroRNAs as a diagnostic tool for heart failure and atrial fibrillation. Curr Opin Pharmacol. 2016; 27:24-30. DOI: 10.1016/j.coph.2016.01.001. View

Whiteside T . The potential of tumor-derived exosomes for noninvasive cancer monitoring. Expert Rev Mol Diagn. 2015; 15(10):1293-310. PMC: 4813325. DOI: 10.1586/14737159.2015.1071666. View

Soeki T, Matsuura T, Bando S, Tobiume T, Uematsu E, Ise T . Relationship between local production of microRNA-328 and atrial substrate remodeling in atrial fibrillation. J Cardiol. 2016; 68(6):472-477. DOI: 10.1016/j.jjcc.2015.12.007. View

Ladomery M, Maddocks D, Wilson I . MicroRNAs: their discovery, biogenesis, function and potential use as biomarkers in non-invasive prenatal diagnostics. Int J Mol Epidemiol Genet. 2011; 2(3):253-60. PMC: 3166153. View

Dobrev D, Nattel S . New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet. 2010; 375(9721):1212-23. DOI: 10.1016/S0140-6736(10)60096-7. View

Cui Y, Zhang X, Yu M, Zhu Y, Xing J, Lin J . Techniques for detecting protein-protein interactions in living cells: principles, limitations, and recent progress. Sci China Life Sci. 2019; 62(5):619-632. DOI: 10.1007/s11427-018-9500-7. View

10.

Li X, Chen L, Wang W, Meng F, Zhao R, Chen Y . MicroRNA-150 Inhibits Cell Invasion and Migration and Is Downregulated in Human Osteosarcoma. Cytogenet Genome Res. 2015; 146(2):124-135. DOI: 10.1159/000437379. View

11.

Oh-Hora M, Rao A . The calcium/NFAT pathway: role in development and function of regulatory T cells. Microbes Infect. 2009; 11(5):612-9. PMC: 2696553. DOI: 10.1016/j.micinf.2009.04.008. View

12.

Wyndham C . Atrial fibrillation: the most common arrhythmia. Tex Heart Inst J. 2000; 27(3):257-67. PMC: 101077. View

13.

Barana A, Matamoros M, Dolz-Gaiton P, Perez-Hernandez M, Amoros I, Nunez M . Chronic atrial fibrillation increases microRNA-21 in human atrial myocytes decreasing L-type calcium current. Circ Arrhythm Electrophysiol. 2014; 7(5):861-8. DOI: 10.1161/CIRCEP.114.001709. View

14.

Molina C, Voigt N . Finding Ms or Mr Right: Which miRNA to target in AF?. J Mol Cell Cardiol. 2016; 102:22-25. DOI: 10.1016/j.yjmcc.2016.11.007. View

15.

Takahashi R, Prieto-Vila M, Hironaka A, Ochiya T . The role of extracellular vesicle microRNAs in cancer biology. Clin Chem Lab Med. 2017; 55(5):648-656. DOI: 10.1515/cclm-2016-0708. View

16.

Zhang J, Jiao J, Cermelli S, Muir K, Jung K, Zou R . miR-21 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Cells. Cancer Res. 2015; 75(9):1859-67. PMC: 4603420. DOI: 10.1158/0008-5472.CAN-14-1254. View

17.

Heijman J, Voigt N, Nattel S, Dobrev D . Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res. 2014; 114(9):1483-99. DOI: 10.1161/CIRCRESAHA.114.302226. View

18.

Andrade J, Khairy P, Dobrev D, Nattel S . The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res. 2014; 114(9):1453-68. DOI: 10.1161/CIRCRESAHA.114.303211. View

19.

Nattel S . Molecular and Cellular Mechanisms of Atrial Fibrosis in Atrial Fibrillation. JACC Clin Electrophysiol. 2018; 3(5):425-435. DOI: 10.1016/j.jacep.2017.03.002. View

20.

Denham N, Pearman C, Caldwell J, Madders G, Eisner D, Trafford A . Calcium in the Pathophysiology of Atrial Fibrillation and Heart Failure. Front Physiol. 2018; 9:1380. PMC: 6180171. DOI: 10.3389/fphys.2018.01380. View